Cardinal Health this week raised its adjusted earnings guidance for fiscal 2026, forecasting at least $10.00 per share compared with its prior range of $9.65 to $9.85. The upward adjustment reflects stronger-than-expected performance in its specialty distribution segment and improved operating leverage. Management cited double-digit volume growth in oncology and rare disease therapies, as well as margin expansion driven by cost-containment initiatives, as key drivers behind the revised outlook. The announcement triggered a notable uptick in trading volumes, underscoring increased investor confidence in Cardinal’s strategic execution.

For fiscal 2026, Cardinal Health reiterated its goal of generating more than $50 billion in specialty revenue, representing a near 15% increase over the prior year. This ambitious target is anchored by expanding partnerships with biopharmaceutical manufacturers and the rollout of new distribution agreements for high-cost therapies. In the oncology channel alone, Cardinal expects to handle over 30% more units of injectable products compared with fiscal 2024. The projected revenue growth is expected to be supported by continued investment in cold-chain logistics and technology automation across its nine specialty distribution centers.

Despite macroeconomic headwinds affecting the broader medical supplies sector, Cardinal Health has outpaced peers through a combination of scale and operational discipline. In the first half of fiscal 2025, the company reported a 6% year-over-year increase in segment gross profit, while its closest competitor achieved 3% growth. Cardinal’s inventory turnover improved by 12 days versus the prior year, driven by enhanced demand forecasting tools and tighter vendor management. Analysts highlight that Cardinal’s ability to integrate acquisitions and leverage its broad customer base—spanning over 20,000 healthcare providers—positions it to deliver market-beating returns even as reimbursement pressures persist.